ArticleIranian journal of child neurology2015
Beta-lactam antibiotics as a possible novel therapy for managing epilepsy and autism, a case report and review of literature.
Article in Iranian journal of child neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Impact of co-amoxiclav-induced gut microbiota modulation on seizure frequency in children with drug-resistant epilepsy.Iranian journal of microbiology · 2026Article
- Plasma EAAT2 and GABA as candidate biomarkers in males with autism spectrum disorder: an exploratory case-control study with ROC analysis.Scientific reports · 2026Article
- Impact of GABA and nutritional supplements on neurochemical biomarkers in autism: a PPA rodent model study.Frontiers in molecular neuroscience · 2025Article
- A long journey to treat epilepsy with the gut microbiota.Frontiers in cellular neuroscience · 2024Review
- Gut microbiota and Autism Spectrum Disorder: From pathogenesis to potential therapeutic perspectives.Journal of traditional and complementary medicine · 2023Review
- Topiramate alters the gut microbiome to aid in its anti-seizure effect.Frontiers in microbiology · 2023Article
- Discovery of (Journal of medicinal chemistry · 2022Article
- The Effect of Ceftriaxone in Valproic Acid-Induced Mouse Model of Autism.Advanced pharmaceutical bulletin · 2022Article
- Gut Microbes Regulate Innate Immunity and Epilepsy.Frontiers in neuroscience · 2022Review
- Fecal Microbiota Transplantation in Neurological Disorders.Frontiers in cellular and infection microbiology · 2020Review
- Commentary on "Beta-Lactam Antibiotics as A Possible Novel Therapy for Managing Epilepsy and Autism.Iranian journal of child neurology · 2018Article
- Pore-Forming Proteins as Mediators of Novel Epigenetic Mechanism of Epilepsy.Frontiers in neurology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism is a disorder of unknown etiology. There are few FDA approved medications for treating autism. Co-occurring autism and epilepsy is common, and glutamate antagonists improve some symptoms of autism. Ceftriaxone, a beta-lactam antibiotic, increases the expression of the glutamate transporter 1 which decreases extracellular glutamate levels. It is hypothesized that modulating astrocyte glutamate transporter expression by ceftriaxone or cefixime might improve some symptoms of autism. This case report of a child with autism and epilepsy suggests a decrease in seizures after taking cefixime.
Indexed as
Identifiers
25767546PMC4322506W1601740522What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.